Share on LinkedInShare on LinkedIn

ARTICLE · 08 DECEMBER 2016

PTAB Holds Oral Hearings In Tecfidera Patent IPR and Interference

On November 30, 2016, the USPTO Patent Trial and Appeal Board (PTAB) held oral hearings in two different inter partes proceedings involving the Biogen Tecfidera® patent with the latest expiation date.

United StatesIntellectual Property

On November 30, 2016, the USPTO Patent Trial and Appeal Board (PTAB) held oral hearings in two different inter partes proceedings involving the Biogen Tecfidera® patent with the latest expiation date. First, it heard arguments in the Inter Partes Review (IPR) brought by Kyle Bass and the Coalition for Affordable Drugs, and then it heard arguments in an interference where Biogen MA Inc. is the junior party against Forward Pharma A/S. While any IPR involving an Orange Book-listed patent attracts a lot of attention, the concurrent interference proceeding makes this case both more complicated and more interesting.

The Tecfidera Patent At Issue

The Tecfidera® patent at issue is U.S. 8,399,514, directed to methods of treating multiple sclerosis. Claim 1 recites:

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from